Stock Fundamentals

Company Information

Company Name
Enanta Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US29251M1062
CIK: 0001177648
CUSIP: 29251M106
Currency: USD
Full Time Employees: 120
Phone: 617 607 0800
Fiscal Year End: September
IPO Date: Mar 21, 2013
Description:

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Address:

4 Kingsbury Avenue, Watertown, MA, United States, 02472

Directors & Officers

Name Title Year Born
Dr. Jay R. Luly Ph.D. President, CEO & Director 1956
Dr. Yat Sun Or Ph.D. Chief Scientific Officer 1952
Dr. Scott T. Rottinghaus M.D. Chief Medical Officer 1974
Mr. Harry R. Trout III VP of Finance & Interim Principal Financial Officer 1969
Ms. Kathleen S. Capps CPA Executive Director of Accounting, Controller & Interim Principal Accounting Officer 1985
Ms. Jennifer Viera Executive Director of Investor Relations & Corporate Communications NA
Mr. Matthew P. Kowalsky J.D. Chief Legal Officer & Corporate Secretary 1973
Mr. Nathaniel S. Gardiner J.D. Consultant 1954
Ms. Tara Lynn Kieffer Ph.D. Chief Product Strategy Officer 1978
Mr. Brendan Luu Chief Business Officer 1975

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 05, 2025 Brendan Luu N/A Sale 1.39K $14.23 $19.84K
Dec 05, 2025 Jay R Luly N/A Sale 4.74K $14.23 $67.49K
Dec 05, 2025 Kathleen S Capps N/A Sale 323.00 $14.23 $4.60K
Dec 05, 2025 Scott T Rottinghaus N/A Sale 798.00 $14.23 $11.36K
Dec 05, 2025 Tara Lynn Kieffer N/A Sale 2.11K $14.23 $29.97K
Dec 05, 2025 Yat Sun Or N/A Sale 2.39K $14.23 $34.01K
Dec 02, 2025 Kathleen S Capps N/A Sale 207.00 $13.96 $2.89K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 3.78M Mar 31, 2026 13.01% $0.02 1.46%
BlackRock Inc 3.10M Mar 31, 2026 10.67% $0.00 0.89%
Farallon Capital Management, L.L.C. 2.87M Mar 31, 2026 9.88% $0.21 3.59%
Krensavage Asset Management, LLC 2.87M Mar 31, 2026 9.86% $14.16 3.61%
Vanguard Group Inc 2.30M Dec 31, 2025 7.92% $0.00 18.72%
Deep Track Capital, LP 1.96M Mar 31, 2026 6.73% $0.40 0.00%
Vanguard Capital Management, LLC 1.18M Mar 31, 2026 4.05% $0.00 0.00%
Vanguard Portfolio Management, LLC 948.90K Mar 31, 2026 3.26% $0.00 0.00%
Spruce Street Capital LP 932.60K Mar 31, 2026 3.21% $2.83 139.32%
Millennium Management LLC 882.10K Mar 31, 2026 3.03% $0.00 31.57%
Acadian Asset Management LLC 880.02K Mar 31, 2026 3.03% $0.02 7,563.70%
Geode Capital Management, LLC 725.06K Mar 31, 2026 2.49% $0.00 12.27%
Renaissance Technologies Corp 665.26K Mar 31, 2026 2.29% $0.01 3.59%
State Street Corp 562.11K Mar 31, 2026 1.93% $0.00 7.33%
Hillsdale Investment Management Inc. 435.51K Mar 31, 2026 1.50% $0.15 3.13%
AQR Capital Management LLC 313.16K Mar 31, 2026 1.08% $0.00 33.35%
Morgan Stanley - Brokerage Accounts 309.51K Mar 31, 2026 1.06% $0.00 -8.95%
Charles Schwab Investment Management Inc 294.97K Mar 31, 2026 1.01% $0.00 34.91%
Two Sigma Investments LLC 267.36K Mar 31, 2026 0.92% $0.00 -6.34%
The Goldman Sachs Group Inc 265.09K Mar 31, 2026 0.91% $0.00 21.15%

Shares Statistics

Shares Outstanding: 29.08M
Shares Float: 20.06M
% Insiders: 468.40%
% Institutions: 9,283.50%
Short % Float: 9.36%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 852.43K 2.93% ▲ 0.00% Apr 30, 2026
2 iShares Russell 2000 ETF 656.26K 2.26% ▲ 0.94% May 29, 2026
3 BlackRock Health Sciences Opps Inv A 492.00K 1.69% ▲ 0.00% Apr 30, 2026
4 Hillsdale US Small Cap Eq Fund Srs A U$ 352.70K 1.21% ▲ 0.00% Dec 31, 2025
5 Vanguard Institutional Extnd Mkt Idx Tr 301.21K 1.04% ▲ 0.71% Apr 30, 2026
6 Vanguard Strategic Small-Cap Equity Inv 280.93K 0.97% ▼ 11.45% Mar 31, 2026
7 Fidelity Small Cap Index 266.64K 0.92% ▲ 0.29% Mar 31, 2026
8 iShares Russell 2000 Value ETF 240.77K 0.83% ▲ 0.00% May 29, 2026
9 iShares Biotechnology ETF 206.08K 0.71% ▲ 1.95% May 29, 2026
10 Vanguard Strategic Equity Inv 180.74K 0.62% ▲ 0.00% Mar 31, 2026

Valuation Metrics

Enterprise Value: $239.09M
Trailing P/E: 0.00
Forward P/E: 44.05

Financial Highlights

Market Cap: $346.03M
EBITDA: $-55.45M
PEG Ratio: $0.00
Book Value: $4.01
Earnings/Share: $-2.60
Profit Margin: -89.56%
Operating Margin: -69.07%
ROA (TTM): -11.84%
ROE (TTM): -59.00%
Revenue (TTM): $69.21M
Revenue/Share (TTM): $2.75
Earnings Growth (YOY): -66.20%
Revenue Growth (YOY): 15.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-09-30 4.21x 0.52x 0.77x -11.11x -0.48x
2024-09-30 5.21x 0.28x 0.66x -11.12x -0.34x
2023-09-30 6.73x 0.02x 0.53x -26.65x -0.04x
2022-09-30 10.45x 0.01x 0.16x -78.73x -0.02x
2021-09-30 8.82x 0.01x 0.09x -20.57x -0.04x
2020-09-30 18.08x 0.01x 0.07x -4.06x -0.11x
2019-09-30 17.77x 0.00x 0.06x 4.17x 0.04x
2018-09-30 23.74x 0.00x 0.05x 18.20x 0.02x
2017-09-30 11.33x 0.00x 0.08x 615.35x 0.03x
2016-09-30 29.43x 0.00x 0.04x 685.36x 0.01x
2015-09-30 25.45x 0.00x 0.04x 15,518.50x 0.00x
2014-09-30 22.75x 0.00x 0.04x 1,054.72x 0.01x
2013-09-30 23.14x 0.00x 0.06x 291.26x 0.00x
2012-09-30 8.25x 0.00x 0.16x N/A 0.00x
2011-09-30 11.68x 0.00x 6.06x 8.00x 0.00x
2010-09-30 N/A N/A N/A N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ENTA.US!